We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




AI Paving the Way for New Generation of Medical Diagnostic Devices

By LabMedica International staff writers
Posted on 22 Aug 2019
Print article
The development of deep learning and neural networks has led to artificial intelligence (AI) gaining learning capabilities, as a result of which some new AI tools are now better than human eyes at recognizing patterns. This is paving the way for the emergence of a new generation of medical diagnostic devices that are capable of surpassing the detection skills of the best medical practitioners.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

The ability to replicate AI has made the expertise of such medical diagnostic devices accessible to a large number of patients. Additionally, AI finds numerous and diverse applications in medical diagnostics, such as image analysis for tumor detection, video detection for gait disorders and fall prediction, biochemical tests such as for diabetes or speech analysis of emotional state and psychiatric disorders. Hence, AI will significantly disrupt the traditional model of medical diagnosis.

Since 2016, companies working on the development of AI for medical imaging have made investments of more than USD 1.1 billion. In addition to big medical diagnostic systems manufacturers, the number of Intellectual Property (IP) newcomers is also important and growing. Unlike as in the case of development of new medical devices, the costs for developing AI software are moderate. As a result, the number of IP newcomers developing innovative software is likely to continue to increase sharply over the coming years.

The emergence of several new companies, coupled with the various advantages and new applications of AI for medical diagnostics, makes it crucial to understand the IP position and strategy of the different players. An analysis of the time evolution of patent publications reveals that the development of medical diagnostic systems with built-in computer-assisted detection features is not new, and the first patents related to this topic were published in the 1980s. During the 1990s, Japanese manufacturers of medical imaging systems began investing in investigations into this field to be soon followed by European companies and later by American companies. The number of patent families published each year increased progressively until 2015 and has increased rapidly since then, with more than 1,100 new patent families published in 2018. This indicates that AI in medical diagnostics is a very hot topic that is mobilizing great R&D efforts from different players.

Among the players who have filed patents related to AI in medical diagnostics, over 90 are newcomers, out of which most are startup firms currently developing their first products. These products include software solutions such as software for ultrasound imaging analysis, image resolution improvement or real-time brain monitoring, or medical devices that are capable of live analysis of biological parameters, such as blood glucose monitoring apparatus, sleep monitoring sensors and ECG. Several IP newcomers are based in the US while some are based in Israel, in Europe or in Asia. Some of these innovative companies could become one of the next healthcare unicorns, making them potential acquisition targets for big corporations.

Related Links:
Research and Markets

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.